- Home
- FLNA vs MCRB Comparison
FLNA vs MCRB Comparison
Compare FLNA & MCRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FLNA | MCRB |
|---|---|---|
| Founded | 1998 | 2010 |
| Country | United States | United States |
| Employees | 20 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 61.8M | 71.0M |
| IPO Year | N/A | 2015 |
Fundamental Metrics
Financial Performance| Metric | FLNA | MCRB |
|---|---|---|
| Price | $1.25 | $5.70 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $14.00 |
| AVG Volume (30 Days) | ★ 346.0K | 52.6K |
| Earning Date | 05-13-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $789,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.16 | $6.01 |
| 52 Week High | $2.03 | $29.98 |
Technical Indicators
Market Signals| Indicator | FLNA | MCRB |
|---|---|---|
| Relative Strength Index (RSI) | 40.61 | 25.77 |
| Support Level | $1.16 | N/A |
| Resistance Level | $1.80 | $9.53 |
| Average True Range (ATR) | 0.10 | 0.68 |
| MACD | -0.00 | -0.13 |
| Stochastic Oscillator | 4.41 | 0.40 |
Price Performance
Historical ComparisonAbout FLNA Filana Therapeutics Inc. Common Stock
Filana Therapeutics Inc is a biotechnology company focused on developing novel, investigational therapies to modulate the filamin A protein for the treatment of central nervous system disorders, such as tuberous sclerosis complex (TSC)-related epilepsy, and other diseases associated with dysregulation or overexpression of filamin A. Its therapeutic product candidate, simufilam, is a proprietary small molecule oral treatment drug being studied for the treatment of TSC-related epilepsy.
About MCRB Seres Therapeutics Inc.
Seres Therapeutics Inc is a clinical-stage biotechnology company focused on the development of live biotherapeutic candidates. Its pipeline includes candidates such as SER-155 and SER-603, aimed at preventing and treating bacterial infections, antimicrobial resistance, and gastrointestinal immune diseases. The company operates as a single reportable segment, mainly developing microbiome-based therapies targeting bacterial infections, antimicrobial resistance, and gastrointestinal immune diseases.